Ann: Prima announces A$1.55m investment from Nyenburg, page-2

SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima” or the “Company”), a leading immuno-oncology company, announces that it has raised €1M (approx. A$1.55M) via a placement of shares at A$0.05 per share (Placement) to Nyenburgh Investment Partners (NYIP).  
Nyenburgh Investment Partners (NYIP), based in the Netherlands, is a specialist healthcare investor. Founded by Alexander Jordaan, Dave van Mastwijk and Ivar van der Salm, NYIP takes long term positions in life sciences companies globally with a specific focus on biotechnology. Further information on NYIP can be found at http://www.nyip.nl.  
The proceeds from the Placement will be used to fund Prima’s IMP321 clinical trial program and provide additional working capital.   
Prima BioMed Chief Executive Officer, Marc Voigt said: “I am very pleased that we are now able to welcome Nyenburgh as a new investor in Prima. This transaction is further evidence of the growing interest levels from sophisticated investors in both the US and Europe in our immunotherapy assets. Following the recent raising from Ridgeback Capital and our successful SPP, this provides important additional funding certainty as we develop IMP321.”  
Alexander Jordaan, Principal of NYIP commented: “We are delighted to make an investment in Prima Biomed since we believe in the potential of their promising pipeline. It perfectly fits in our investment portfolio